Witty Wishes Everyone Would Hold Off On GSK Break-Up Chatter
This article was originally published in Scrip
Executive Summary
There is an "extraordinarily low" likelihood of GlaxoSmithKline Plc. spinning off its consumer healthcare business within the next three years, said CEO Andrew Witty. Getting the margin structure right of the joint venture with Novartis was a "three year journey" and despite making "great progress" in 2015, there was still work to be done. "Time is everybody's friend here," said Witty, speaking during the presentation of GSK's annual results and fourth quarter financials on Feb. 3rd.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.